Skip to Content

Generic Xarelto Availability

Xarelto is a brand name of rivaroxaban, approved by the FDA in the following formulation(s):

XARELTO (rivaroxaban - tablet;oral)

Has a generic version of Xarelto been approved?

No. There is currently no therapeutically equivalent version of Xarelto available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xarelto. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Substituted oxazolidinones and their use in the field of blood coagulation
    Patent 7,157,456
    Issued: January 2, 2007
    Inventor(s): Straub; Alexander & Lampe; Thomas & Pohlmann; Jens & Röhrig; Susanne & Perzborn; Elisabeth & Schlemmer; Karl-Heinz & Pernerstorfer; Joseph
    Assignee(s): Bayer HealthCare AG
    The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
    Patent expiration dates:
    • August 28, 2024
      ✓ 
      Patent use: TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • August 28, 2024
      ✓ 
      Patent use: TREATMENT OF PULMONARY EMBOLISM (PE)
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Substituted oxazolidinones and their use in the field of blood coagulation
    Patent 7,585,860
    Issued: September 8, 2009
    Inventor(s): Straub; Alexander & Lampe; Thomas & Pohlmann; Jens & Rohrig; Susanne & Perzborn; Elisabeth & Schlemmer; Karl-Heinz & Pernerstorfer; Joseph
    Assignee(s): Bayer Schering Pharma Aktiengesellschaft
    The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
    Patent expiration dates:
    • December 11, 2020
      ✓ 
      Drug substance
  • Substituted oxazolidinones and their use in the field of blood coagulation
    Patent 7,592,339
    Issued: September 22, 2009
    Inventor(s): Straub; Alexander & Lampe; Thomas & Pohlmann; Jens & Rohrig; Susanne & Perzborn; Elisabeth & Schlemmer; Karl-Heinz & Pernerstorfer; Joseph
    Assignee(s): Bayer Schering Pharma Aktiengesellschaft
    The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
    Patent expiration dates:
    • December 11, 2020
      ✓ 
      Patent use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
    • December 11, 2020
      ✓ 
      Patent use: REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM
    • December 11, 2020
      ✓ 
      Patent use: REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
    • December 11, 2020
      ✓ 
      Patent use: TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
    • December 11, 2020
      ✓ 
      Patent use: TREATMENT OF PULMONARY EMBOLISM (PE)
  • Solid, orally administrable pharmaceutical composition
    Patent 9,415,053
    Issued: August 16, 2016
    Assignee(s): Bayer Intellectual Property GmbH
    The present invention relates to a process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide in hydrophilized form, and its use for the prophylaxis and/or treatment of diseases.
    Patent expiration dates:
    • November 13, 2024
      ✓ 
      Patent use: REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM
      ✓ 
      Drug product
    • November 13, 2024
      ✓ 
      Patent use: TREATMENT OF PULMONARY EMBOLISM (PE)
      ✓ 
      Drug product
    • November 13, 2024
      ✓ 
      Patent use: TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
      ✓ 
      Drug product
    • November 13, 2024
      ✓ 
      Patent use: REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
      ✓ 
      Drug product
    • November 13, 2024
      ✓ 
      Patent use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
      ✓ 
      Drug product
  • Prevention and treatment of thromboembolic disorders
    Patent 9,539,218
    Issued: January 10, 2017
    Assignee(s): BAYER INTELLECTUAL PROPERTY GMBH
    The present invention relates to the field of blood coagulation, more specifically it relates to a method of treating a thromboembolic disorder by administering once daily a direct factor Xa inhibitor in oral dosage form to a patient in need thereof, wherein the factor Xa inhibitor has a plasma concentration half life indicative of a bid or tid administration interval, e.g. of 10 hours or less.
    Patent expiration dates:
    • February 17, 2034
      ✓ 
      Patent use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM IN PATIENTS UNDERGOING KNEE OR HIP REPLACEMENT SURGERY, WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
    • February 17, 2034
      ✓ 
      Patent use: TREATMENT OF DEEP VEIN THROMBOSIS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
    • February 17, 2034
      ✓ 
      Patent use: TREATMENT OF PULMONARY EMBOLISM WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
    • February 17, 2034
      ✓ 
      Patent use: REDUCE THE RISK OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
    • February 17, 2034
      ✓ 
      Patent use: FOLLOWING INITIAL 6 MONTHS TREATMENT FOR DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE), REDUCTION IN THE RISK OF RECURRENCE OF DVT AND OF PE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 1, 2016 - NEW CHEMICAL ENTITY
Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide